Rochester, NY 9/1/2009 4:02:53 PM
Cardium Therapeutics Inc., CXM, Up by 2.73% Last Trading
Cardium Therapeutics Inc.
Cardium Therapeutics reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.
As reported in the Journal of the American Academy of Physician Assistants, (JAAPA, August 2009), chronic wounds affect an estimated 5.7 million patients in the U.S. and cost the healthcare system approximately $20 billion annually. The article's author further notes that optimal wound care requires a portfolio of treatments including the only FDA-approved protein-based topical gel Regranex® (becaplermin), bioengineered skin substitutes, hyperbaric oxygen therapy, and subatmospheric wound therapy (also known as negative-pressure wound therapy), as well as institutional support from the growing number of nationwide wound-care centers that offer specialized, multidisciplinary approaches to the treatment of chronic wounds.
Whisperfromwallstreet.com is a FREE award winning newsletter dedicated to uncovering stocks that are about to move. Please click here to join now.
Last Trade: 1.88
Day's Range: N/A - N/A
52wk Range: 0.00 - 3.10
Change: 0.00 (0.00%)
Volume: 0
Avg Vol (3m): 165,206
ABOUT Cardium Therapeutics, Inc.
Cardium Therapeutics, Inc. (Cardium) is a medical technology development-stage company. The Company is primarily focused on the development, manufacture and sale of therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium owns a portfolio of biologic growth factors and related delivery techniques, acquired from the Schering AG Group, for potential use in treating ischemic and other cardiovascular conditions. Cardium owns rights to the assets and technologies of Tissue Repair Company, a company focused on the development of growth factor therapeutics for the potential treatment of tissue wounds, such as chronic diabetic wounds. Tissue Repair Company is operated as a wholly owned subsidiary of Cardium. In July 2009, the Company completed the asset sale of its InnerCool Therapies business to Koninklijke Philips Electronics NV
ABOUT WhisperFromWallStreet.com
WhisperFromWallStreet.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
WhisperFromWallStreet.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://WhisperFromWallStreet.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
